Smith; Christopher Ronald
Patent Applications and Registrations
Patent applications and USPTO patent grants for Smith; Christopher Ronald.The latest application filed is for "tetrahydropyridopyrimidine pan-kras inhibitors".
- Smith; Christopher Ronald - San Diego CA
- Smith; Christopher Ronald - Sandwich GB
| Patent | Date |
|---|---|
| KRas G12D inhibitors Grant 11,453,683 - Wang , et al. September 27, 2 | 2022-09-27 |
| Tetrahydropyridopyrimidine Pan-kras Inhibitors App 20220194961 - Wang; Xiaolun ; et al. | 2022-06-23 |
| Sos1 Inhibitors App 20210188857 - Marx; Matthew Arnold ; et al. | 2021-06-24 |
| MTA-Cooperative PRMT5 Inhibitors App 20210078994 - Bobinski; Thomas P. ; et al. | 2021-03-18 |
| MTA-Cooperative PRMT5 Inhibitors App 20210079003 - Bobinski; Thomas P. ; et al. | 2021-03-18 |
| Kras G12c Inhibitors App 20200331911 - Marx; Matthew Arnold ; et al. | 2020-10-22 |
| Kras G12c Inhibitors App 20200308170 - Marx; Matthew Arnold ; et al. | 2020-10-01 |
| Kras G12c Inhibitors App 20200262837 - Marx; Matthew Arnold ; et al. | 2020-08-20 |
| KRas G12C inhibitors Grant 10,689,377 - Blake , et al. | 2020-06-23 |
| ASK1 isoindolin-1-one inhibitors and methods of use thereof Grant 10,654,833 - Smith , et al. | 2020-05-19 |
| KRas G12C inhibitors Grant 10,647,715 - Marx , et al. | 2020-05-12 |
| Ask1 Isoindolin-1-one Inhibitors And Methods Of Use Thereof App 20200002312 - Smith; Christopher Ronald ; et al. | 2020-01-02 |
| Kras G12c Inhibitors App 20190270743 - Marx; Matthew Arnold ; et al. | 2019-09-05 |
| Kras G12c Inhibitors App 20190144444 - Blake; James F. ; et al. | 2019-05-16 |
| Bicyclic triazoles as protein kinase modulators Grant 8,507,489 - Bounaud , et al. August 13, 2 | 2013-08-13 |
| Triazolopyridazine protein kinase modulators Grant 8,071,581 - Smith , et al. December 6, 2 | 2011-12-06 |
| Substituted triazole derivatives as oxytocin antagonists Grant 7,875,615 - Brown , et al. January 25, 2 | 2011-01-25 |
| Triazolopyridazine Protein Kinase Modulators App 20100120739 - Smith; Christopher Ronald ; et al. | 2010-05-13 |
| Substituted Triazole Derivatives As Oxytocin Antagonists App 20100063064 - Brown; Alan Daniel ; et al. | 2010-03-11 |
| Substituted triazole derivatives as oxytocin antagonists Grant 7,649,003 - Brown , et al. January 19, 2 | 2010-01-19 |
| Bicyclic Triazoles As Protein Kinase Modulators App 20090258855 - Bounaud; Pierre-Yves ; et al. | 2009-10-15 |
| Heterocyclic Kinase Modulators App 20090156594 - Bounaud; Pierre-Yves ; et al. | 2009-06-18 |
| Substituted Triazole Derivatives as Oxytocin Antagonists App 20080108625 - Brown; Alan Daniel ; et al. | 2008-05-08 |
| Substituted triazole derivatives as oxytocin antagonists Grant 7,291,640 - Brown , et al. November 6, 2 | 2007-11-06 |
| Novel compounds of proline and morpholine derivatives App 20050261290 - Cheng, Hengmiao ; et al. | 2005-11-24 |
| Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 App 20050148631 - Cheng, Hengmiao ; et al. | 2005-07-07 |
| Oxytocin inhibitors Grant 6,914,160 - Armour , et al. July 5, 2 | 2005-07-05 |
| Substituted triazole derivatives as oxytocin antagonists App 20050107382 - Brown, Alan Daniel ; et al. | 2005-05-19 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 